.
The Federal Health Minister, Greg Hunt, announced today, $25M of funding to CTx partner, WEHI, to boost Australia’s capacity to perform compound screening, the first stage along the path of produc...
Cancer Therapeutics CRC (CTx) is pleased to announce the appointment of Dr Brendon Monahan as Chief Scientific Officer. Brendon will succeed Dr Ian Street who was co-founder of CTx in 2007, and who wi...
Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Pfizer w...
Mark is the founder and CEO of Medicines Development for Global Health, a small Melbourne based not-for-profit drug development company. Passionately focused on developing drugs for diseases with high...
Of the 129 children enrolled in the trial from across Australia with high-risk and relapsed cancers, 67% were provided with personalised treatment plans aimed at killing their unique cancer cells. For...
In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer t...